Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer

Biomaterials

Volumn 34, Issue 27, 2013, Pages 6444-6453

  Kim, Insoo ^a   Byeon, Hyeong Jun ^a   Kim, Tae Hyung ^a   Lee, Eun Seong ^b   Oh, Kyung Taek ^c   Shin, Beom Soo ^d   Lee, Kang Choon ^a   Youn, Yu Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Chung Ang University   (South Korea)

^d Catholic University of Daegu   (South Korea)

Author keywords

Doxorubicin; Inhalation; Lung cancer; Porous microparticles; Synergism; TNF related apoptosis inducing ligand

Indexed keywords

DOXORUBICIN; INHALATION; LUNG CANCER; MICRO-PARTICLES; SYNERGISM;

BIOLOGICAL ORGANS; CELL DEATH; DISEASES; DRUG INTERACTIONS; EMULSIFICATION; MAMMALS;

COPOLYMERS;

AMMONIUM DERIVATIVE; DOXORUBICIN; NANOPARTICLE; POLY(D,L LACTIC CO GLYCOLIC ACID); TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG POTENTIATION; EMULSION; HUMAN; HUMAN CELL; LUNG CANCER; MALE; METASTASIS; MOUSE; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; POROSITY; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

ADMINISTRATION, INHALATION; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; HUMANS; LACTIC ACID; LUNG; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; POLYGLYCOLIC ACID; POROSITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

MUS;

EID: 84879093304     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.05.018     Document Type: Article

References (40)

1. Wauthoz N., Deleuze P., Hecq J., Roland I., Saussez S., Adanja I., et al. Invivo assessment of temozolomide local delivery for lung cancer inhalation therapy. Eur J Pharm Sci 2010, 39:402-411.
2. Garbuzenko O.B., Saad M., Pozharov V.P., Reuhl K.R., Mainelis G., Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A 2010, 107:10737-10742.
3. Tseng C.L., Wu S.Y., Wang W.H., Peng C.L., Lin F.H., Lin C.C., et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008, 29:3014-3022.
4. Roa W.H., Azarmi S., Al-Hallak M.H., Finlay W.H., Magliocco A.M., Lobenberg R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. JControl Release 2011, 150:49-55.
5. Kim I., Byeon H.J., Kim T.H., Lee E.S., Oh K.T., Shin B.S., et al. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer. Biomaterials 2012, 33:5574-5583.
6. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007, 6:67-74.
7. Youn Y.S., Lee K.C., Bae Y.H., Na K., Lee E.S. Advanced pulmonary delivery of peptides or proteins using polymeric particles. Delivery technologies for biopharmaceuticals: peptides, proteins, nucleic acids, and vaccines 2009, 228-244. WILEY. L. Jorgensen, H.M. Nielsen (Eds.).
8. Patton J.S., Fishburn C.S., Weers J.G. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004, 1:338-344.
9. Mobley C., Hochhaus G. Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov Today 2001, 6:367-375.
10. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005, 5:876-885.
11. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. JBiol Chem 1996, 271:12687-12690.
12. Almasan A., Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003, 14:337-348.
13. Singh T.R., Shankar S., Chen X., Asim M., Srivastava R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma invivo. Cancer Res 2003, 63:5390-5400.
14. Tsai W.S., Yeow W.S., Chua A., Reddy R.M., Nguyen D.M., Schrump D.S., et al. Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin. Mol Cancer Ther 2006, 5:2977-2990.
15. Fan Q.L., Zou W.Y., Song L.H., Wei W. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines invitro and invivo. Cancer Chemother Pharmacol 2005, 55:189-196.
16. El-Zawahry A., McKillop J., Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 2005, 5:2.
17. Jiang C.C., Chen L.H., Gillespie S., Kiejda K.A., Mhaidat N., Wang Y.F., et al. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res 2007, 67:5880-5888.
18. Kim H., Park H., Lee J., Kim T.H., Lee E.S., Oh K.T., et al. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. Biomaterials 2011, 32:1685-1693.
19. Kim H., Lee J., Kim T.H., Lee E.S., Oh K.T., Lee D.H., et al. Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes. Pharm Res 2011, 28:2008-2019.
20. Kim T.K., Yoon J.J., Lee D.S., Park T.G. Gas foamed open porous biodegradable polymeric microspheres. Biomaterials 2006, 27:152-159.
21. Bae S., Ma K., Kim T.H., Lee E.S., Oh K.T., Park E.S., et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 2012, 33:1536-1546.
22. Jiang H.H., Kim T.H., Lee S., Chen X., Youn Y.S., Lee K.C. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy. Biomaterials 2011, 32:8529-8537.
23. Kim T.H., Jiang H.H., Park C.W., Youn Y.S., Lee S., Chen X., et al. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity. JControl Release 2011, 150:63-69.
24. Kim T.H., Jo Y.G., Jiang H.H., Lim S.M., Youn Y.S., Lee S., et al. PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting. JControl Release 2012, 162:422-428.
25. Lee J., Lee C., Kim T.H., Lee E.S., Shin B.S., Chi S.C., et al. Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system. JControl Release 2012, 161:728-734.
26. Shiraga M., Yano S., Yamamoto A., Ogawa H., Goto H., Miki T., et al. Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. Cancer Res 2002, 62:5967-5973.
27. Scheuch G., Kohlhaeufl M.J., Brand P., Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006, 58:996-1008.
28. Borgstrom L., Olsson B., Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. JAerosol Med 2006, 19:473-483.
29. McFadden E.R. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. JAllergy Clin Immunol 1995, 96:278-283.
30. Melani A.S., Canessa P., Coloretti I., DeAngelis G., DeTullio R., Del Donno M., et al. Inhaler mishandling is very common in patients with chronic airflow obstruction and long-term home nebuliser use. Respir Med 2012, 106:668-676.
31. Otterson G.A., Villalona-Calero M.A., Hicks W., Pan X., Ellerton J.A., Gettinger S.N., et al. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res 2010, 16:2466-2473.
32. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., et al. Large porous particles for pulmonary drug delivery. Science 1997, 276:1868-1871.
33. Edwards D.A., Ben-Jebria A., Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. JAppl Physiol 1998, 85:379-385.
34. Yang Y., Bajaj N., Xu P., Ohn K., Tsifansky M.D., Yeo Y. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 2009, 30:1947-1953.
35. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand invivo. Nat Med 1999, 5:157-163.
36. Thorburn A., Behbakht K., Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat 2008, 11:17-24.
37. Stegehuis J.H., de Wilt L.H., de Vries E.G., Groen H.J., de Jong S., Kruyt F.A. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist Updat 2010, 13:2-15.
38. Raja S.M., Chen S., Yue P., Acker T.M., Lefkove B., Arbiser J.L., et al. The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Mol Cancer Ther 2008, 7:2212-2223.
39. Belyanskaya L.L., Marti T.M., Hopkins-Donaldson S., Kurtz S., Felley-Bosco E., Stahel R.A. Human agonistic TRAIL receptor antibodies mapatumumab and lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 2007, 6:66.
40. Shankar S., Chen X., Srivastava R.K. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer invitro and invivo. Prostate 2005, 62:165-186.